Updated international consensus report on the investigation and management of primary immune thrombocytopenia

Drew Provan(Queen Mary University of London), David J. Kuter(Harvard University)
Blood Advances
November 26, 2019
10.1182/bloodadvances.2019000812
Cited by 1,070

Related Papers

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP
|New England Journal of Medicine|2006|530
A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia
|Blood|2014|162
Serum free light chain analysis
|American Journal of Hematology|2010|107
Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-Week Update.
|Blood|2006|30